title: Industry funded clinical trials: bias and quality.
abstract: The quality of the clinical data supporting the development and ultimately the approval for medical use of new drugs is often challenged. Many share the perception that the business goals of the pharmaceutical industry overrule the best scientific efforts to accrue critical knowledge on a new molecule, in order to inform investment of resources, regulatory approvals and appropriate use by patients. Despite this common belief, few scientists have attempted to assess objectively the quality of industry funded (IF) clinical trials by measuring it and comparing it with non-industry funded (NIF) clinical trials in a data-driven fashion. Overall, the average quality of IF clinical research has been reported to be higher than the quality of NIF clinical research.
authors: angelodelp@gmail.com
authors: Angelo
authors: A
authors: Del Parigi
mesh_terms: D015982:Bias; D035843:Biomedical Research / Q000191:economics* / Q000941:ethics / Q000331:legislation & jurisprudence; D002986:Clinical Trials as Topic / Q000191:economics* / Q000941:ethics / Q000592:standards* / Q000706:statistics & numerical data; D016265:Conflict of Interest; D004345:Drug Industry / Q000191:economics* / Q000941:ethics; D005069:Evaluation Studies as Topic; D005376:Financial Management; D005380:Financing, Government / Q000706:statistics & numerical data; D006801:Humans; D011787:Quality of Health Care / Q000191:economics / Q000592:standards; D012107:Research Design / Q000592:standards / Q000706:statistics & numerical data